Cormorant Asset Management LP has recently announced that it has increased stake in Alpine Immune Sciences Inc (NASDAQ:ALPN) by 50.00%. After grabbing 2.85 million shares, the institutional investor is now in possession of 0.95 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 4.91% having worth around $54.32 million. Moreover, BlackRock Fund Advisors increased its share by 58518.0 to have a control over 2.16 million shares. And The Vanguard Group, Inc. raised its holdings to 54870.0 shares by acquiring 1.41 million shares or 2.44% of the stake.
Alpine Immune Sciences Inc (ALPN) concluded trading on Thursday at a closing price of $21.74, with 2.94 million shares of worth about $63.9 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 84.24% during that period and on Thursday, January 25 the price saw a gain of about 17.13%. Currently the company’s common shares owned by public are about 45.98M shares, out of which, 41.05M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 4 times over the past 12 months. They bought 760,989 shares in 3 of the transactions. In 1 selling transactions, insiders dumped 18,003 shares.
Vanguard Total Stock Market ETF, T Rowe Price New Horizons Fund, and iShares Russell 2000 ETF are the top 3 mutual funds which are holding stakes in Alpine Immune Sciences Inc Vanguard Total Stock Market ETF is currently holding 1.27 million shares of worth totaling $24.23 million. The company recently came buying 0.0 shares which brought its stake up to 2.19% of the company’s outstanding shares. T Rowe Price New Horizons Fund bought 0.24 million shares, after which its hold over company’s outstanding shares expand to 1.91%, leaving 1.11 million shares with the mutual fund that have a worth of about $21.08 million. iShares Russell 2000 ETF, after selling 0.88 million shares, have now control over 1.52% of the stake in the company. It holds 2322.0 shares of worth $16.77 million.
However, the stock later moved at a day high price of 22.00, or with a gain of 17.13%. Stock saw a price change of 12.35% in past 5 days and over the past one month there was a price change of 11.95%. Year-to-date (YTD), ALPN shares are showing a performance of 14.06% which increased to 170.40% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.39 but also hit the highest price of $20.94 during that period. The average intraday trading volume for Alpine Immune Sciences Inc shares is 810.30K. The stock is currently trading 11.84% above its 20-day simple moving average (SMA20), while that difference is up 25.70% for SMA50 and it goes to 74.69% higher than SMA200.
Cormorant Asset Management LP acquired 2.85 million shares of Alpine Immune Sciences Inc having value of about $54.32 million. Data submitted at the U.S SEC by Cormorant Asset Management LP revealed that the firm now holds 0.95 million shares in the company valued at close to $20653000.0, or have control over 50.00% stake in the company. Alpine Immune Sciences Inc (NASDAQ: ALPN) currently have 45.98M outstanding shares and institutions hold larger chunk of about 55.02% of that. Holding of mutual funds in the company is about 33.10% while other institutional holders and individual stake holders have control over 38.57% and 16.45% of the stake respectively.
The stock has a current market capitalization of $1.26B and its 3Y-monthly beta is at 1.06. It has posted earnings per share of -$1.20 in the same period. It has Quick Ratio of 3.81 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALPN, volatility over the week remained 6.85% while standing at 5.33% over the month.
Analysts are in expectations that Alpine Immune Sciences Inc (ALPN) stock would likely to be making an EPS of -$0.31 in the current quarter, while forecast for next quarter EPS is -$0.34 and it is -$1.34 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.58 which is -$0.2 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.41 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 38.15% while it is estimated to decrease by -23.63% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Berenberg on October 18, 2023 offering a Buy rating for the stock and assigned a target price of $18 to it.
